6533b839fe1ef96bd12a5ac7

RESEARCH PRODUCT

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

Mario Adelfio LatteriAmato CCalogero CipollaVittorio GebbiaGabriella LampasonaNicolo' Gebbia

subject

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusiness

description

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a very intense regimen-i.e. the ProMACE-Cytabom-because of the unfavourable histology, while the two patients with primary breast non-Hodgkin lymphoma received less aggressive CHOP and CVP chemotherapy. All patients are still alive and free of disease 3 to 6 years after initial diagnosis. These cases stress the systemic nature of non-Hodgkin lymphomas even if apparently localized to a single extranodal organ. Thus, although a definitive therapeutic strategy cannot be drawn from the rare and occasional reports in the medical literature, primary extranodal lymphomas require integrated multimodality therapy with radiotherapy and/or chemotherapy. © 1995 W.B. Saunders Company Limited.

https://doi.org/10.1016/s0748-7983(95)92945-2